FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. Delvadia PR, Nookala A R, Gottipati G, Sabarinath S, Uppoor RS, Mehta MU, Du X, Wang Y-MC, Dokmanovic M, Myers R, et al. J Clin Pharmacol. 2026 Aug; 66(8):e70257. PMID: 42572211. Abstract CommentRecommendBookmarkWatch
